FMP
Evelo Biosciences, Inc.
EVLO
NASDAQ
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
0.0005 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Craig R. Jalbert CIRA
sector
Healthcare
industry
Biotechnology
website
https://www.evelobio.comexchange
NASDAQ
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. E...
CIK
0001694665
ISIN
US2997342025
CUSIP
299734103
Address
620 Memorial Drive
Phone
617 577 0300
Country
US
Employee
66
IPO Date
May 8, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
EVLO Financial Summary
CIK
0001694665
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
299734103
ISIN
US2997342025
Country
US
Price
0
Beta
1.3
Volume Avg.
957
Market Cap
9.49k
Shares
-
52-Week
1.0E-4-0.075
DCF
3.59
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.evelobio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EVLO News
It looks like there's no news available.
